126 related articles for article (PubMed ID: 38519275)
1. Exploratory pilot study to characterize the immune landscapes of malignant pleural effusions and their corresponding primary tumors from patients with breast carcinoma and lung adenocarcinoma.
Laberiano-Fernandez C; Gan Q; Wang SM; Tamegnon A; Wistuba I; Yoon E; Roy-Chowdhuri S; Parra ER
J Am Soc Cytopathol; 2024; 13(3):161-173. PubMed ID: 38519275
[TBL] [Abstract][Full Text] [Related]
2. Migrated T lymphocytes into malignant pleural effusions: an indicator of good prognosis in lung adenocarcinoma patients.
Nieto JC; Zamora C; Porcel JM; Mulet M; Pajares V; Muñoz-Fernandez AM; Calvo N; Espinosa I; Pascual-García M; Bielsa S; Vidal S
Sci Rep; 2019 Feb; 9(1):2996. PubMed ID: 30816121
[TBL] [Abstract][Full Text] [Related]
3. Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.
Zou Y; Xu L; Tang Q; You Q; Wang X; Ding W; Zhao J; Ren G
BMC Cancer; 2020 Apr; 20(1):344. PubMed ID: 32321471
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung.
Wang S; Chen H; Zhong J; Qin H; Bai H; Zhao J; Wang J
Lung Cancer; 2019 Sep; 135():116-122. PubMed ID: 31446983
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusions.
Lieser EA; Croghan GA; Nevala WK; Bradshaw MJ; Markovic SN; Mansfield AS
Lung Cancer; 2013 Oct; 82(1):63-8. PubMed ID: 23948549
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary Adenocarcinoma in Malignant Pleural Effusion Enriches Cancer Stem Cell Properties during Metastatic Cascade.
Chen SF; Lin YS; Jao SW; Chang YC; Liu CL; Lin YJ; Nieh S
PLoS One; 2013; 8(5):e54659. PubMed ID: 23658677
[TBL] [Abstract][Full Text] [Related]
7. The PD-L1/PD-1 pathway promotes dysfunction, but not "exhaustion", in tumor-responding T cells from pleural effusions in lung cancer patients.
Prado-Garcia H; Romero-Garcia S; Puerto-Aquino A; Rumbo-Nava U
Cancer Immunol Immunother; 2017 Jun; 66(6):765-776. PubMed ID: 28289860
[TBL] [Abstract][Full Text] [Related]
8. EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors.
Yang J; Lee OJ; Son SM; Woo CG; Jeong Y; Yang Y; Kwon J; Lee KH; Han HS
Cancer Res Treat; 2018 Jul; 50(3):908-916. PubMed ID: 28934846
[TBL] [Abstract][Full Text] [Related]
9. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
10. Malignant pleural effusion supernatants are substitutes for metastatic pleural tumor tissues in EGFR mutation test in patients with advanced lung adenocarcinoma.
Liu D; Lu Y; Hu Z; Wu N; Nie X; Xia Y; Han Y; Li Q; Zhu G; Bai C
PLoS One; 2014; 9(2):e89946. PubMed ID: 24587142
[TBL] [Abstract][Full Text] [Related]
11. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity.
Roscilli G; De Vitis C; Ferrara FF; Noto A; Cherubini E; Ricci A; Mariotta S; Giarnieri E; Giovagnoli MR; Torrisi MR; Bergantino F; Costantini S; Fenizia F; Lambiase M; Aurisicchio L; Normanno N; Ciliberto G; Mancini R
J Transl Med; 2016 Feb; 14():61. PubMed ID: 26928703
[TBL] [Abstract][Full Text] [Related]
12. Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients.
Thompson JC; Fan R; Black T; Yu GH; Savitch SL; Chien A; Yee SS; Sen M; Hwang WT; Katz SI; Feldman M; Vachani A; Carpenter EL
Lung Cancer; 2019 Jan; 127():25-33. PubMed ID: 30642547
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.
Feng M; Zhu J; Liang L; Zeng N; Wu Y; Wan C; Shen Y; Wen F
Int J Clin Oncol; 2017 Apr; 22(2):283-290. PubMed ID: 27990560
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions.
Kasapoglu US; Arınç S; Gungor S; Irmak I; Guney P; Aksoy F; Bandak D; Hazar A
Clin Respir J; 2016 Nov; 10(6):791-799. PubMed ID: 25764010
[TBL] [Abstract][Full Text] [Related]
15. Useful Application of Immunostaining to Malignant Pleural Effusion among Lao People in Vientiane Capital, Lao PDR.
Vilayvong S; Hando K; Sekine M; Luangxay T; Arounlangsy P; Xaysomphet P; Xayaphet P; Thavisouk H; Soejima Y; Kitagawa M; Sawabe M
Asian Pac J Cancer Prev; 2019 Jan; 20(1):243-248. PubMed ID: 30678439
[TBL] [Abstract][Full Text] [Related]
16. Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid.
Scherpereel A; Grigoriu BD; Noppen M; Gey T; Chahine B; Baldacci S; Trauet J; Copin MC; Dessaint JP; Porte H; Labalette M
BMC Cancer; 2013 Jul; 13():324. PubMed ID: 23816056
[TBL] [Abstract][Full Text] [Related]
17. Survival of lung adenocarcinoma patients with malignant pleural effusion.
Wu SG; Yu CJ; Tsai MF; Liao WY; Yang CH; Jan IS; Yang PC; Shih JY
Eur Respir J; 2013 Jun; 41(6):1409-18. PubMed ID: 23018906
[TBL] [Abstract][Full Text] [Related]
18. Utility of Claudin-4 versus BerEP4 and B72.3 in pleural fluids with metastatic lung adenocarcinoma.
Patel A; Borczuk AC; Siddiqui MT
J Am Soc Cytopathol; 2020; 9(3):146-151. PubMed ID: 32184064
[TBL] [Abstract][Full Text] [Related]
19. CD39 identifies a specific CD8 + T cell population in lung adenocarcinoma-related metastatic pleural effusion.
Lv LL; Wang HB; Zhang YX; Zhai JW; Shen Y; Qu QX; Chen C
BMC Immunol; 2023 Dec; 24(1):53. PubMed ID: 38087217
[TBL] [Abstract][Full Text] [Related]
20. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
